Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

被引:148
作者
Caramazza, D. [2 ]
Begna, K. H. [1 ]
Gangat, N. [1 ]
Vaidya, R. [1 ]
Siragusa, S. [2 ]
Van Dyke, D. L. [3 ]
Hanson, C. [4 ]
Pardanani, A. [1 ]
Tefferi, A. [1 ]
机构
[1] Mayo Clin, Div Hematol, Dept Med, Rochester, MN 55905 USA
[2] Policlin Univ Palermo, Cattedra & UO Ematol, Palermo, Italy
[3] Mayo Clin, Cytogenet Div, Dept Lab Med, Rochester, MN 55905 USA
[4] Mayo Clin, Div Hematopathol, Dept Lab Med, Rochester, MN 55905 USA
关键词
myelofibrosis; karyotype; cytogenetics; prognosis; myeloproliferative; INTERNATIONAL WORKING GROUP; PROGNOSTIC SCORING SYSTEM; POLYCYTHEMIA-VERA; MYELOPROLIFERATIVE NEOPLASMS; ESSENTIAL THROMBOCYTHEMIA; MYELOID METAPLASIA; ALLELE BURDEN; JAK2V617F; DISORDERS; DISEASE;
D O I
10.1038/leu.2010.234
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have previously identified sole +9, 13q- or 20q-, as 'favorable' and sole +8 or complex karyotype as 'unfavorable' cytogenetic abnormalities in primary myelofibrosis (PMF). In this study of 433 PMF patients, we describe additional sole abnormalities with favorable (chromosome 1 translocations/duplications) or unfavorable (-7/7q-) prognosis and also show that other sole or two abnormalities that do not include i(17q), -5/5q-, 12p-, inv(3) or 11q23 rearrangement are prognostically aligned with normal karyotype, which is prognostically favorable. These findings were incorporated into a refined two-tired cytogenetic-risk stratification: unfavorable and favorable karyotype. The respective 5-year survival rates were 8 and 51% (hazard ratio (HR): 3.1, 95% confidence interval (CI): 2.2-4.3; P<0.0001). Multivariable analysis confirmed the International Prognostic Scoring System (IPSS)-independent prognostic value of cytogenetic-risk categorization and also identified thrombocytopenia (platelets <100 x 10(9)/l) as another independent predictor of inferior survival (P<0.0001). A similar multi-variable analysis showed that karyotype (P = 0.001) and platelet count (P = 0.04), but not IPSS (P = 0.27), predicted leukemia-free survival; the 5-year leukemic transformation rates for unfavorable versus favorable karyotype were 46 and 7% (HR: 5.5, 95% CI: 2.5-12.0; P<0.0001). This study provides the rationale and necessary details for incorporating cytogenetic findings and platelet count in future prognostic models for PMF. Leukemia (2011) 25, 82-88; doi: 10.1038/leu.2010.234; published online 14 October 2010
引用
收藏
页码:82 / 88
页数:7
相关论文
共 28 条
  • [1] Outcome of Transplantation for Myelofibrosis
    Ballen, Karen K.
    Shrestha, Smriti
    Sobocinski, Kathleen A.
    Zhang, Mei-Jie
    Bashey, Asad
    Bolwell, Brian J.
    Cervantes, Francisco
    Devine, Steven M.
    Gale, Robert Peter
    Gupta, Vikas
    Hahn, Theresa E.
    Hogan, William J.
    Kroeger, Nicolaus
    Litzow, Mark R.
    Marks, David I.
    Maziarz, Richard T.
    McCarthy, Philip L.
    Schiller, Gary
    Schouten, Harry C.
    Roy, Vivek
    Wiernik, Peter H.
    Horowitz, Mary M.
    Giralt, Sergio A.
    Arora, Mukta
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (03) : 358 - 367
  • [2] Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders
    Cervantes, F.
    Passamonti, F.
    Barosi, G.
    [J]. LEUKEMIA, 2008, 22 (05) : 905 - 914
  • [3] New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
    Cervantes, Francisco
    Dupriez, Brigitte
    Pereira, Arturo
    Passamonti, Francesco
    Reilly, John T.
    Morra, Enrica
    Vannucchi, Alessandro M.
    Mesa, Ruben A.
    Demory, Jean-Loup
    Barosi, Giovanni
    Rumi, Elisa
    Tefferi, Ayalew
    [J]. BLOOD, 2009, 113 (13) : 2895 - 2901
  • [4] THE EFFICACY OF DIRECT, 24-HOUR CULTURE, AND MITOTIC SYNCHRONIZATION METHODS FOR CYTOGENETIC ANALYSIS OF BONE-MARROW IN NEOPLASTIC HEMATOLOGIC DISORDERS
    DEWALD, GW
    BRODERICK, DJ
    TOM, WW
    HAGSTROM, JE
    PIERRE, RV
    [J]. CANCER GENETICS AND CYTOGENETICS, 1985, 18 (01) : 1 - 10
  • [5] Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
    Guglielmelli, Paola
    Barosi, Giovanni
    Specchia, Giorgina
    Rambaldi, Alessandro
    Lo Coco, Francesco
    Antonioli, Elisabetta
    Pieri, Lisa
    Pancrazzi, Alessandro
    Ponziani, Vanessa
    Delaini, Federica
    Longo, Giovanni
    Ammatuna, Emanuele
    Liso, Vincenzo
    Bosi, Alberto
    Barbui, Tiziano
    Vannucchi, Alessandro M.
    [J]. BLOOD, 2009, 114 (08) : 1477 - 1483
  • [6] Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation
    Gupta, Raavi
    Soupir, Chad P.
    Johari, Vandita
    Hasserjian, Robert P.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (02) : 265 - 268
  • [7] The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan
    Hidaka, Tomonori
    Shide, Kotaro
    Shimoda, Haruko
    Kameda, Takurou
    Toyama, Keiko
    Katayose, Keiko
    Kubuki, Youko
    Nagata, Kenji
    Takenaka, Katsuto
    Akashi, Koichi
    Okamura, Takashi
    Niho, Yoshiyuki
    Mizoguchi, Hideaki
    Omine, Mitsuhiro
    Ozawa, Keiya
    Harada, Mine
    Shimoda, Kazuya
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 83 (04) : 328 - 333
  • [8] Risk factors for leukemic transformation in patients with primary myelofibrosis
    Huang, Jocelin
    Li, Chin-Yang
    Mesa, Ruben A.
    Wu, Wentling
    Hanson, Curtis A.
    Pardanani, Animesh
    Tefferi, Ayalew
    [J]. CANCER, 2008, 112 (12) : 2726 - 2732
  • [9] International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis
    Hussein, Kebede
    Pardanani, Animesh D.
    Van Dyke, Daniel L.
    Hanson, Curtis A.
    Tefferi, Ayalew
    [J]. BLOOD, 2010, 115 (03) : 496 - 499
  • [10] Choosing between stem cell therapy and drugs in myelofibrosis
    Kroeger, N.
    Mesa, R. A.
    [J]. LEUKEMIA, 2008, 22 (03) : 474 - 486